After completion of the review by Pharmaceuticals and Medical Devices Agency (PMDA), the following anticancer drugs were approved for non-small cell lung cancer (NSCLC) in Japan on Aug 28, 2024 [1]. (1) ALK inhibitor alectinib as adjuvant treatment inALKfusion gene-positive NSCLC In the ALIN...
What is Imfinzi used for?Imfinzi indications are non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer, hepatocellular carcinoma, endometrial cancer, and muscle invasive bladder cancer (MIBC) in specific patients. Imfinzi is an FDA-approved prescription medicine ...
In August, the FDA approved Xalkori (crizotinib) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. The abnormal ALK gene is detected by the Vysis ALK Break Apart FISH Probe Kit, a test the FDA also appr...
Alectinib (Alecensa) is a type of cancer medication used to treat non-small cell lung cancer (NSCLC) in people who have an error in their anaplastic lymphoma kinase (ALK) gene.
(Yun et al.2020). The tyrosine kinase inhibitorrepotrectinibwas approved for locally advanced or metastatic ROS1-positive NSCLC. Repotrectinib received priority review, breakthrough, and fast track designation. The most common AE are dizziness, taste disorder, peripheral neuropathy, constipation, ...
Osimertinib NSCLC 2015/11/13 2016/2/1 2017/3/22 16.3 Erlotinib NSCLC 2004/11/18 2005/9/19 2006/4/6 16.6 Crizotinib ALK positive NSCLC 2011/8/26 2012/10/23 2013/1/22 16.9 Crizotinib ROS-1 positive NSCLC 2016/3/11 2016/9/29 2017/9/25 18.5 Gefitinib NSCLC 2003/5/5 2009/6/24 ...
Zykadia (ceritinib) is a tyrosine kinase inhibitor that was approved by FDA on April 29, 2014, as a medication for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant ...
approved for NSCLC as the initial indication, and most of them are classified as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors. Therefore,EGFRmutation andALKrearrangement tests are recommended for NSCLC before EGFR- or ALK-directed therapies [8,9] (Fig.2a...
Figure 1. China Food and Drug Administration (CFDA)/National Medical Product Administration (NMPA)-approved China innovative anti-lung cancer drugs. ALK: Anaplastic lymphoma kinase; EGFR: Epidermal growth factor receptor; MET: Mesenchymal-epithelial transition factor; NSCLC: Non-small cell lung cancer...
Currently, the family of Platinum derivatives can be divided into compounds that have been approved for treatment around the world, such as Cisplatin, Carboplatin, Oxaliplatin, and those that are only used in selected countries, such as Nedaplatin, Heptaplatin and Lobaplatin, taken by patients ...